BioLine Rx (BioLine Rx) Days Inventory : 0.00 (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is BioLine Rx Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). BioLine Rx's Average Total Inventories for the three months ended in Dec. 2023 was $1.65 Mil. BioLine Rx's Cost of Goods Sold for the three months ended in Dec. 2023 was $0.00 Mil.

The historical rank and industry rank for BioLine Rx's Days Inventory or its related term are showing as below:

During the past 13 years, BioLine Rx's highest Days Inventory was 193.09. The lowest was 193.09. And the median was 193.09.

BLRX's Days Inventory is not ranked ^*
in the Biotechnology industry.
Industry Median: 192.63
* Ranked among companies with meaningful Days Inventory only.

BioLine Rx's Days Inventory stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

Inventory Turnover measures how fast the company turns over its inventory within a year. BioLine Rx's Inventory Turnover for the three months ended in Dec. 2023 was 0.00.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. BioLine Rx's Inventory-to-Revenue for the three months ended in Dec. 2023 was 0.34.

BioLine Rx Days Inventory Historical Data

The historical data trend for BioLine Rx's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Days Inventory Chart

BioLine Rx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Inventory

Get a 7-Day Free Trial

193.08

BioLine Rx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of BioLine Rx's Days Inventory

For the Biotechnology subindustry, BioLine Rx's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLine Rx's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's Days Inventory distribution charts can be found below:

* The bar in red indicates where BioLine Rx's Days Inventory falls into.

BioLine Rx Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

BioLine Rx's Days Inventory for the fiscal year that ended in Dec. 2023 is calculated as

	Days Inventory (A: Dec. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (0	+	1.953)	/	1 )	/	3.692	*	365
=	1.953					/	3.692	*	365
=	193.08

BioLine Rx's Days Inventory for the quarter that ended in Dec. 2023 is calculated as:

	Days Inventory (Q: Dec. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (Q: Sep. 2023 )	+	Total Inventories (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (1.352	+	1.953)	/	2 )	/	0	*	365 / 4
=	1.6525					/	0	*	365 / 4
=	N/A

BioLine Rx (NAS:BLRX) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

BioLine Rx's Inventory Turnover for the three months ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	1.6525
	=	0.00

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

BioLine Rx's Inventory to Revenue for the three months ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	1.6525	/	4.8
	=	0.34

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

BioLine Rx Days Inventory Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLine Rx (BioLine Rx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (NAS:BLRX) » Definitions » Days Inventory

Comparable Companies

Traded in Other Exchanges

BLRX:Israel YP2A:Germany YP2A:Germany

Address

2 HaMa’ayan Street, Modi’in, ISR, 7177871

Website

https://www.biolinerx.com

BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.